TG Therapeutics, Inc. has announced robust financial results for the third quarter of 2026, leading the company to raise its full-year revenue guidance to approximately $1 billion. This update is significant as it underscores the company’s growth trajectory and the successful performance of its BRIUMVI product line, a key player in the pharmaceutical preparations sector.
On November 9, 2026, TG Therapeutics revealed its financial performance for the three and nine months ending September 30, 2026. The company reported total global revenue of approximately $260 million for the third quarter, with U.S. net product revenue from BRIUMVI reaching around $233 million. This performance reflects a strong year-over-year increase and positions the company favorably in the competitive landscape.
Background
TG Therapeutics, Inc. is a pharmaceutical company incorporated in Delaware and traded on the Nasdaq under the ticker symbol TGTX. The company specializes in the development and commercialization of innovative therapies for patients with serious diseases, particularly in the field of pharmaceutical preparations (SIC: 2834). Recent filings indicate a proactive approach in expanding its product offerings and enhancing its market presence.
What the Filing Says
The recent SEC filing notes, "On November 9, 2026, the Company issued a press release announcing results of operations for the three and nine months ended September 30, 2026." Additionally, it states that the company has raised its full-year 2026 total global revenue guidance to approximately $1 billion, up from the previous estimate of $950 million.
Impact
This updated guidance is expected to positively affect various stakeholders, including investors, employees, and healthcare providers. Investors may view the increased revenue outlook as a sign of the company’s strong market position and growth potential. Employees could benefit from enhanced job security and potential bonuses tied to company performance, while healthcare providers may gain access to more resources and innovative treatments.
What's Next
Looking ahead, TG Therapeutics anticipates several important developments, including pivotal Phase 3 results for subcutaneous BRIUMVI expected by early 2027. The company is also preparing for a potential launch of simplified intravenous initiation in mid-2027, which could further enhance its market position.
In summary, TG Therapeutics’ strong Q3 results and raised revenue guidance reflect a positive outlook for the company and its stakeholders. As the pharmaceutical industry continues to evolve, companies like TG Therapeutics will likely play a critical role in shaping the future of healthcare.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










